Navigation Links
T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role
Date:4/4/2008

Researchers at the Burnham Institute for Medical Research (Burnham) may have found a new option for targeted breast cancer therapy by showing the link between a certain protein and the formation and development of blood vessels that feed breast tumors. Like mortar between bricks in a wall, T-cadherin is a protein that helps cells stick together and collectively form tissues. Cancer cells that loosen their adhesive tissue bonds stop producing T-cadherin, and in tumors, only the blood vessels that supply oxygen and nutrients express this protein. Now, Barbara Ranscht, Ph.D., and Robert Oshima, Ph.D., at Burnham have led a team that developed the first living model to study this proteins effect on tumor angiogenesis by creating a strain of mice that develops spontaneous mammary gland tumors in the absence of T-cadherin. Their results appeared March 1 in Cancer Research.

Evidence of T-cadherins role in vascularization has been somewhat controversial, explains Dr. Ranscht, senior author of the study, which includes Drs. Lionel Hebbard and Michle Garlatti from the Burnham Institute as equally contributing first authors and Drs. Robert Cardiff and Lawrence Young as collaborators from the University of California, Davis. But our knockout model clearly shows that T-cadherin plays a role in promoting tumor vascularization, with implications for tumor growth and animal survival.

The tumor model developed in Dr. Ranschts laboratory shows that loss of T-cadherin slows down tumor growth and improves survival compared to controls where T-cadherin is present: The absence of T-cadherin delays tumor growth by an average of 10 days, decreases tumor size, and apoptosis markers, indicators of cell suicide, are six times higher. The tumor-bearing knockouts live an average of 18.5 days longer than their wild-type counterparts, which translates into approximately 18 months of human life span.

The normal models in the study developed solid adenocarcino
'/>"/>

Contact: Andrea Moser
amoser@burnham.org
858-646-3146
Burnham Institute
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Study finds pitching mound height affects throwing motion, injury risk
2. Gene dose affects tumor growth
3. Restless legs syndrome affects nearly 2 percent of US/UK children
4. Gender, coupled with diabetes, affects vascular disease development
5. Umbilical cord blood cell therapy may reduce signs and symptoms of Alzheimers disease
6. Umbilical cord blood cell therapy in an animal model of Alzheimers disease
7. Blood vessel protein reverses macular degeneration, diabetic retinopathy in mice
8. Diabetes makes it hard for blood vessels to relax
9. Weill Cornell team discovers how brains own tPA helps regulate blood flow to neurons
10. High blood pressure in older adults traced to genes effects in blood vessels
11. Eltrombopag effective for hepatitis C patients with low blood-platelet counts
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role
T-cadherin affects blood vessel growth in breast cancer, hormone from fat cells may play a role
(Date:8/29/2008)... biological clock may have just gotten a little lo...a report that the number of genes under control of...ago. The biological clock in a much-studied model ...ported. The new study implies that the clock may b...elp to explain why the clock is so far-reaching in...
(Date:8/28/2008)...on from the atomic bomb blasts in Hiroshima and Na...mes in some survivors who later developed papillar...researchers. , In the September 1, 2008, issue o...ociation for Cancer Research, the scientists repor..., were comparably young at the time, and developed...
(Date:8/28/2008)...e discovery of the first new living species of gia...e published online on August 28th in Current Biol...nce reveals that the new species, called Tridacna... of giant clams in the Red Sea, it now represents ... , The researchers said they cannot say for sure...
(Date:8/28/2008)...le lizards begin and end the day with displays of ...nsions of a colorful neck flap, or dewlap -- to de... "Anoles are highly visual species, so in that se...l displays to mark territory," said Terry J. Ord, ...rd University,s Museum of Comparative Zoology. The...
Breaking Biology News(10 mins):Study shows more genes are controlled by biological clocks 2Study shows more genes are controlled by biological clocks 3Researchers discover atomic bomb effect results in adult-onset thyroid cancer 2New giant clam species offers window into human past 2Feats of strength begin a lizard's day 2BioMS Medical to Present at Acumen BioFin Rodman 26 Renshaw 9th Annual Healthcare Conference 5069 1BioMS Medical to Present at Acumen BioFin Rodman 26 Renshaw 9th Annual Healthcare Conference 5069 2HearAtLast Teams Up with American Express and Wal Mart to Conquer Hearing Loss 5067 1HearAtLast Teams Up with American Express and Wal Mart to Conquer Hearing Loss 5067 2HearAtLast Teams Up with American Express and Wal Mart to Conquer Hearing Loss 5067 3HearAtLast Teams Up with American Express and Wal Mart to Conquer Hearing Loss 5067 4XTL Announces Delisting From the Official List of the United Kingdom Listing Authority 5065 1XTL Announces Delisting From the Official List of the United Kingdom Listing Authority 5065 2XTL Announces Delisting From the Official List of the United Kingdom Listing Authority 5065 3King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 1King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 2King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 3King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 4King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 5King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion 5063 6
...he United States and other northern mid- and upper...fsetting global warming than previously thought, a.... The study, which sheds light on the so-called mi...forests are removing an unexpectedly high proporti...y offsetting carbon entering the air through indus...
...t has again vetoed the Stem Cell Research Enhancem...bryonic stem cell research. AAAS, the world’s larg...d coalition of Americans spanning all parties and ...onsensus is that embryonic stem cell research is a...effective treatments for devastating conditions li...
...th the oral antiviral Tamiflu (oseltamivir) and pr...could be one of the most cost-effective strategies...a pandemic. According to modelling research presen..., a stockpile of Tamiflu sufficient to cover 65% o...ximately half. This study was announced at the lea...
...ting our feelings into words — talking with a ther... feel better" A new brain imaging study by UCLA ps...akes our sadness, anger and pain less intense. , ...e of the same members of the research team, combin...ings to provide the first neural evidence for why ...
Other Biology News:Scientists close in on missing carbon sink 2Scientists close in on missing carbon sink 3AAAS decries latest stem cell veto 2AAAS decries latest stem cell veto 3Experts predict Tamiflu could halve the pandemic influenza death toll versus no intervention 2Putting feelings into words produces therapeutic effects in the brain 2Putting feelings into words produces therapeutic effects in the brain 3Putting feelings into words produces therapeutic effects in the brain 4Putting feelings into words produces therapeutic effects in the brain 5
(Date:8/28/2008).... 28 /- Truman Medical Centers (TMC),...ates to install the,Siemens SOMATOM Definition AS ...canner is a highly adaptive scanner, providing exc...sure to the patient., "To be one of the first med..., first of its kind, state-of-the-art technology c...
(Date:8/28/2008)...28 /- Barr Pharmaceuticals,...diary, Barr Laboratories,Inc., received final app...A) to manufacture and market a generic version of ...drobromide), 4 mg, 8 mg and 12 mg tablets. Barr,in...ct immediately., Barr filed an Abbreviated New Dr...
(Date:8/28/2008)...st 28 /- ThromboGenics NV,(...ocused on innovative,treatments for eye disease, v...iness update and its financial results for the six...irst half of 2008, ThromboGenics has achieved a nu...ompany to successfully pursue the,next stage of it...
(Date:8/28/2008)... CoreValve ( www.corevalve.com ) announced today t...uation of its proprietary percutaneous ReValving S...mounted in a self-expanding frame, was initiated l...f. (Business Wire EON) August 28, 2008 -- The fir...ystem were performed in two days by John Ormiston,...
Breaking Biology Technology:Truman Medical Centers Becomes One of the First Hospitals in the U.S. To Install the World's First Adaptive 128-slice CT Scanner 2Barr Receives Approval for Generic Version of Razadyne(R) Tablets 2Barr Receives Approval for Generic Version of Razadyne(R) Tablets 3Barr Receives Approval for Generic Version of Razadyne(R) Tablets 4Barr Receives Approval for Generic Version of Razadyne(R) Tablets 5ThromboGenics Announces Half Year Results 2008 2ThromboGenics Announces Half Year Results 2008 3ThromboGenics Announces Half Year Results 2008 4ThromboGenics Announces Half Year Results 2008 5 CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries 2
... FLEXSTATION IS A FLEXIBLE TOOL FOR ASSAY DEVELOP...PERIMENTAL SET-UP , EASY DATA ANALYSIS , ...TATION OR FLIPR , , Introduction ...nduces the flow of calcium ions out of intracellul...ascade. Cell signaling through calcium mobilizatio...
...N FOR DIVERSIFIED TARGETS, , , , ,...NADHERENT CELL TYPES , , HIGHER SIGNAL I... , COMPATIBLE WITH MORE TARGETS , , ...mobilization assays for screening GPCR targets are...ey generate high quality leads. Molecular Devices ...
....D. and Michael Su, M.S., , Molec...UCTION , Immunoassays have traditionally em...dilutions of samples were necessary to ensure that...Recently, chemiluminescent immunoassays, with grea...ecome commercially available 1 . The QuantiGlo TNF...
...nc., 6519 Dumbarton Circle, Fremont, CA 94555. ,...mediated gene expression knockdown studies is the ...e Reagent System and the Molecular Devices LMax II...IL-8 mRNA in PMA-induced HeLa cells, following siR...down discerned differences of less than 10% in mRN...
Other Biology Technology:Gq-coupled receptor assays: a comparison of FLEXstation and FLIPR 2Gq-coupled receptor assays: a comparison of FLEXstation and FLIPR 3FLIPR Calcium 3 Assay Kit Datasheet 2FLIPR Calcium 3 Assay Kit Datasheet 3High Sensitivity, Wide Dynamic Range, Horseradish Peroxidase (HRP) ELISA Using the LMax Microplate Luminometer (MaxLine Application Note #41) 2High Sensitivity, Wide Dynamic Range, Horseradish Peroxidase (HRP) ELISA Using the LMax Microplate Luminometer (MaxLine Application Note #41) 3Measuring siRNA-mediated knockdown of IL-8 mRNA 2Measuring siRNA-mediated knockdown of IL-8 mRNA 3Measuring siRNA-mediated knockdown of IL-8 mRNA 4
... 3000 power supply, 220-240 V, is used for protein...ectric focusing (IEF). The system includes both th...ers, chassis, harvesting apparatus, cooling finger...10 ml Bio-Lyte ampholytes (pH 3-10), 60 ml syringe...
...s used for protein separation and purification by ...m includes both the mini (18 ml) and standard (60 ...us, cooling finger, electrode chambers, 10 ml Bio-...protein sample, 2 vent buttons, and one each of th...
SIGNETs BCIP/NBT Chromogen system consists of [5-Bromo-4-Chloro-3-,Indolyl Phosphate/Nitro Blue Tetrazolium] chromogen in a single component,solution. The ready-to-use BCIP/NBT solution reacts in
Mouse monoclonal antibody raised against a partial recombinant VEGFB. NCBI Entrez Gene ID = VEGFB
Biology Products: